News

Editor's picks

Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.
Image © monkeybusinessimages / Getty Images / iStock
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
Image © Choreograph / Getty Images / iStock
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Image © Bildagentur Online / Picture Alliance

Latest headlines

Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.
Children with X-linked hypophosphatemia derive similar benefits from burosumab regardless of whether they start treatment before or after the age of 5 years, shows a post-hoc analysis of a randomised trial.
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
Children’s weight trajectories between birth and 4 years of age are associated with their dehydroepiandrosterone sulphate levels at age 7 years, study findings show.
A large study shows that growth in the first 5 years of life is associated with age at pubertal onset.
Blood-cell markers of inflammation are elevated in children with Cushing’s syndrome and may offer useful diagnostic information, say researchers.
Researchers recommend next-generation sequencing for the first-line diagnosis of patients with 46,XY differences of sex development.
Martin Savage
Programme Director

Sign up for eAlerts

Be the first to hear about new resources and content by signing up to receive our eAlerts.

Please provide your details:

Follow us
This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.
medwireNews is an independent clinical news service provided by Springer Healthcare Limited. © 2022 Springer Healthcare is part of the Springer Nature Group